Trials / Sponsors / Phanes Therapeutics
Phanes Therapeutics
Industry · 3 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC) | Phase 1 / Phase 2 | 2023-09-05 |
| Recruiting | Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC) | Phase 1 / Phase 2 | 2023-03-15 |
| Recruiting | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combinati Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | 2022-08-11 |